共 50 条
Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen
被引:11
|作者:
Aksoy, Evrim Kahramanoglu
[1
]
Sapmaz, Ferdane Pirincci
[1
]
Goktas, Zeynep
[2
]
Uzman, Metin
[1
]
Nazligul, Yasar
[1
]
机构:
[1] Hacettepe Univ, Kecloren Training & Res Hosp, Dept Gastroenterol, Sanatoryum Caddesi Ardahan Sokak D 25, TR-06280 Ankara, Turkey
[2] Hacettepe Univ, Kecloren Training & Res Hosp, Dept Nutr & Dietet, Fac Hlth Sci, Ankara, Turkey
关键词:
Helicobacter pylori infection;
Bismuth-containing quadruple therapy;
Levofloxacin-containing triple therapy;
Eradication rate;
RESCUE REGIMENS;
EFFICACY;
CLARITHROMYCIN;
RESISTANCE;
METAANALYSIS;
INFECTION;
D O I:
10.1159/000484930
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Objective: The aim of this study was to compare the efficacy and safety of 2-week levofloxacin-containing triple therapy, levofloxacin-containing bismuth quadruple therapy, and standard bismuth-containing quadruple therapy as a firstline regimen for the eradication of Helicobacter pylori. Methods: A total of 329 patients with H. pylori infection were randomly divided into 3 groups to receive one of the following regimens: (a) levofloxacin-containing bismuth quadruple therapy RBAL (rabeprazole 20 mg, b.i.d., bismuth subsalicylate 562 mg, b.i.d., amoxicillin 1 g, b.i.d, levofloxacin 500 mg, once daily), (b) standard bismuth quadruple therapy, RBMT (rabeprazole 20 mg, b.i.d, subsalicylate 562 mg, b.i.d., metronidazole 500 mg, t.i.d, tetracycline 500 mg, q.i.d), or (c) levo-floxacin-containing triple therapy, RAL (rabeprazole 20 mg, b.i.d., amoxicillin 1 g, b.i.d, levofloxacin 500 mg, once daily). The primary outcome was the eradication rate in the intention-to-treat (ITT) and per protocol (PP) analysis. Results: The eradication rates of the above 3 groups using ITT analysis were RBAL 83.8%, RBMT 88.3%, and RAL 74.8% compared with 91.2, 92.5, and 79.2%, respectively, using PP analysis. The eradication rate using RBMT was significantly higher than that of RAL (p = 0.029 in ITT analysis and p = 0.017 in PP analysis). Several side effects occurred in 156 patients (54.1%) in the RBAL group, 215 (52.3%) in the RBMT group, and 56 (26.2%) in the RAL group (p > 0.05, RBAL vs. RBMT; p < 0.001, RBMT vs. RAL; p < 0.001, RBAL vs. RAL). Conclusion: All bismuth-containing quadruple therapies had acceptable eradication rates, but levofloxacin-containing triple therapy was not as good as quadruple therapies. Hence, quadruple therapies should be considered the preferred first-line therapy for H. pylori infections. (C) 2017 The Author(s) Published by S. Karger AG, Basel
引用
收藏
页码:523 / 529
页数:7
相关论文